Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Argan Inc

AGX NYSE Construction - Special Trade Contractors Financials FY2017–FY2026

Argan Inc had $945M of revenue in fiscal 2026, up 8.1% on the year before. Over five years, revenue changed +19.2% a year on average.

Today
0.5%
Previous close
$331.03
Market cap
$4.7B
P/E
26.1x
52-week range
$292.22 $798.55

Last close Β· Oct 26, 2026

$329.34

+$32.79 (+11.06%) past year

Share price

Argan Inc

What Argan Inc does

AGX Β· Construction - Special Trade Contractors

From its latest annual report

No business description yet.

Filing details

Legal name
ARGAN INC
Fiscal year ends
January 31, 2026
Latest annual report
10-K Β· Mar 26, 2026
Accession Β· CIK
0001104659-26-035216 Β· 0000100591

Earnings calendar Β· Argan Inc

Every quarter, companies publish how much they sold and earned. These are the days Argan Inc did it, and the next one. Share prices often move a lot on those days.

Next results

December 3, 2026

Thursday Β· in 37 days

Time
Time not announced
Covers
Period ended Oct 31, 2026
Expected EPS
$3.34
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Sep 2, 2026 Q2 '27 After the market closes 8-K β†—
Jun 4, 2026 Q1 '27 After the market closes 8-K β†—
Mar 26, 2026 Q4 '26 After the market closes 8-K β†—
Dec 4, 2025 Q3 '26 After the market closes 8-K β†—
Sep 4, 2025 Q2 '26 After the market closes 8-K β†—
Jun 4, 2025 Q1 '26 After the market closes 8-K β†—
Mar 27, 2025 Q4 '25 After the market closes 8-K β†—
Dec 5, 2024 Q3 '25 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Argan Inc’s latest annual report (fiscal 2026). Here is what stands out:

4 strengths

1.Sales and profit

See section β†’
  • Argan Inc had $945M of revenue in fiscal 2026, up 8.1% on the year before. Over five years, revenue changed +19.2% a year on average.
  • Its operating margin was 14.3%, up 4.2Β pts: of every 100 in sales, about 14 is left after running the business.
  • Argan Inc made $138M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 9.0% a year.

2.Cash and shareholders

See section β†’
  • Free cash flow was $411M in fiscal 2026, 43.5% of revenue.
  • Argan Inc returned $34.2M to shareholders in fiscal 2026, 8% of free cash flow. The diluted share count rose 1.7%.
  • In the last 12 months, insiders sold $147M of shares on the open market and bought none.

Argan Inc in 30 seconds

Good So-so Weak

Good

Are sales growing?

+8.1%

Yes. Sales grew 8.1% last year.

Good

Does it make a profit?

14.6%

Yes. It keeps 14.6% of every sale as profit.

Good

Does profit turn into cash?

43.5%

Yes. 43.5% of sales ends up as free cash.

So-so

How healthy are the accounts?

5 / 8

Mixed. It passes 5 of 8 health tests.

For information

How is the share priced?

26.1x

One share costs 26.1 times its yearly profit per share.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2026

Market cap Last close times the latest diluted share count, so it is approximate.
$4.7B
Oct 26 close
P/E Last close divided by diluted earnings per share over the last four quarters.
26.1x
On $12.64 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Argan Inc had $945M of revenue in fiscal 2026, up 8.1% on the year before. Over five years, revenue changed +19.2% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was 14.3%, up 4.2Β pts: of every 100 in sales, about 14 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Argan Inc made $138M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 9.0% a year.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $411M in fiscal 2026, 43.5% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA Β· Argan Inc had $945M of revenue in fiscal 2026, up 8.1% on the year before. Over five years, revenue changed +19.2% a year on average. Its operating margin was 14.3%, up 4.2Β pts: of every 100 in sales, about 14 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Argan Inc made $138M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 9.0% a year.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was $411M in fiscal 2026, 43.5% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Argan Inc returned $34.2M to shareholders in fiscal 2026, 8% of free cash flow. The diluted share count rose 1.7%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders sold $147M of shares on the open market and bought none.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$147M

11 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Jul 31, 2026 John Ronald Jeffrey Jr.Director Sold 5,716 $579.64 $3.3M Form 4
Jun 22, 2026 William F Griffin JrDirector, Gemma, Non-Executive Chairman Sold 20,000 $760.43 $15.2M Form 4
Jun 18, 2026 William F Griffin JrDirector, Gemma, Non-Executive Chairman Sold 30,000 $725.85 $21.8M Form 4
Jun 17, 2026 Peter W GetsingerDirector Sold 2,000 $699.00 $1.4M Form 4
Jun 17, 2026 Karen SweeneyDirector Sold 300 $705.00 $0.2M Form 4
Jun 17, 2026 Joshua Scott BaugherChief Financial Officer Sold 760 $733.30 $0.6M Form 4
Jun 16, 2026 Peter W GetsingerDirector Sold 4,728 $708.65 $3.4M Form 4
Jun 16, 2026 David Hibbert WatsonPresident and CEO, Director Sold 1,880 $707.35 $1.3M Form 4
Jun 15, 2026 Cynthia FlandersDirector Sold 2,596 $666.31 $1.7M Form 4
Jun 15, 2026 David Hibbert WatsonPresident and CEO, Director Sold 9,993 $651.22 $6.5M Form 4
Jun 12, 2026 William F Griffin JrDirector, Gemma, Non-Executive Chairman Sold 50,000 $643.46 $32.2M Form 4
Apr 29, 2026 Alexander Lisa LarroqueDirector Sold 350 $630.58 $0.2M Form 4
Apr 29, 2026 Peter W GetsingerDirector Sold 3,000 $628.36 $1.9M Form 4
Apr 28, 2026 William F. LeimkuhlerDirector Sold 5,800 $617.75 $3.6M Form 4
Apr 27, 2026 John Ronald Jeffrey Jr.Director Sold 2,698 $664.84 $1.8M Form 4
Apr 21, 2026 Charles Edwin Collins IVChief Executive Officer, Gemma Sold 11,068 $621.61 $6.9M Form 4
Apr 21, 2026 John Ronald Jeffrey Jr.Director Sold 3,636 $615.40 $2.2M Form 4
Apr 20, 2026 Charles Edwin Collins IVChief Executive Officer, Gemma Sold 2,500 $610.00 $1.5M Form 4
Apr 17, 2026 David Hibbert WatsonPresident and CEO, Director Sold 19,310 $602.11 $11.6M Form 4
Apr 16, 2026 Joshua Scott BaugherChief Financial Officer Sold 600 $605.60 $0.4M Form 4
Apr 13, 2026 William F. LeimkuhlerDirector Sold 8,444 $598.49 $5.1M Form 4
Apr 2, 2026 Peter W GetsingerDirector Sold 2,581 $552.73 $1.4M Form 4
Mar 31, 2026 John Ronald Jeffrey Jr.Director Sold 4,556 $539.85 $2.5M Form 4
Jan 27, 2026 John Ronald Jeffrey Jr.Director Sold 5,000 $360.78 $1.8M Form 4
Jan 21, 2026 Cynthia FlandersDirector Sold 19,000 $386.70 $7.3M Form 4
Jan 20, 2026 John Ronald Jeffrey Jr.Director Sold 2,700 $380.60 $1.0M Form 4
Jan 16, 2026 William F. LeimkuhlerDirector Sold 11,044 $379.15 $4.2M Form 4
Jan 13, 2026 William F. LeimkuhlerDirector Sold 4,212 $320.53 $1.4M Form 4
Jan 12, 2026 William F. LeimkuhlerDirector Sold 2,164 $318.28 $0.7M Form 4
Jan 8, 2026 Peter W GetsingerDirector Sold 6,595 $313.71 $2.1M Form 4
Jan 7, 2026 Peter W GetsingerDirector Sold 4,000 $328.34 $1.3M Form 4
Dec 23, 2025 William F. LeimkuhlerDirector Sold 200 $337.47 $0.1M Form 4
Dec 10, 2025 James W QuinnDirector Sold 1,000 $328.04 $0.3M Form 4
Oct 20, 2025 Peter W GetsingerDirector Sold 6,493 $294.39 $1.9M Form 4
Oct 17, 2025 Peter W GetsingerDirector Sold 2,000 $292.00 $0.6M Form 4
Oct 15, 2025 Charles Edwin Collins IVChief Executive Officer, Gemma Sold 10,000 $309.37 $3.1M Form 4
Oct 13, 2025 Charles Edwin Collins IVChief Executive Officer, Gemma Sold 10,000 $292.09 $2.9M Form 4
Oct 9, 2025 David Hibbert WatsonPresident and CEO, Director Sold 5,000 $276.48 $1.4M Form 4
Oct 8, 2025 Cynthia FlandersDirector Sold 15,000 $271.96 $4.1M Form 4
Oct 1, 2025 Charles Edwin Collins IVChief Executive Officer, Gemma Sold 5,000 $275.00 $1.4M Form 4
Oct 1, 2025 William F. LeimkuhlerDirector Sold 11,802 $274.73 $3.2M Form 4
Sep 30, 2025 James W QuinnDirector Sold 13,444 $269.12 $3.6M Form 4
Sep 29, 2025 John Ronald Jeffrey Jr.Director Sold 4,698 $268.60 $1.3M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Argan Inc can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $350M$325M$307M$298M$491M
Current ratio 2.3x2.2x1.8x1.6x1.6x
Quick ratio 2.3x2.2x1.8x1.6x1.6x
Total assets $554M$489M$598M$836M$1.2B
Total liabilities $228M$209M$307M$484M$724M
Shareholders' equity $326M$281M$291M$352M$462M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Argan Inc passes 5 of 8 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Cash from operations is positive βœ“ βœ• βœ• βœ“ βœ“ βœ“ βœ• βœ“ βœ“ βœ“
Return on assets rose β€” βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ“ βœ“ βœ• βœ• βœ“ βœ• βœ• βœ• βœ•
Share count didn't rise β€” βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ“ βœ• βœ•
Gross margin rose β€” βœ• βœ“ βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ“
Revenue rose relative to assets β€” βœ“ βœ• βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ•
F-score β€” / 34 / 84 / 83 / 86 / 86 / 83 / 85 / 86 / 85 / 8
Accruals ratio βˆ’29.3%24.4%32.2%βˆ’20.0%βˆ’27.9%1.7%12.1%βˆ’15.5%βˆ’11.5%βˆ’27.4%
Altman Z'' 5.248.2811.916.665.306.526.545.324.984.88

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue $675M $893M $482M $239M $392M $509M $455M $573M $874M $945M
Provision for credit losses β€” β€” β€” $0.0M $0.0M $2.4M $0.1M β€” β€” β€”
Gross profit $147M $149M $82.4M βˆ’$6.8M $62.1M $99.7M $86.4M $80.8M $141M $194M
Operating income $112M $107M $40.2M βˆ’$55.8M $23.0M $44.5M $41.7M $36.5M $88.2M $135M
Pretax income $115M $113M $47.2M βˆ’$47.8M $24.9M $47.1M $46.0M $48.9M $111M $161M
Income tax $37.1M $40.3M βˆ’$4.7M βˆ’$7.1M $1.1M $11.4M $11.3M $16.6M $25.7M $22.7M
Net income $70.3M $72.0M $52.0M βˆ’$42.7M $23.9M $38.2M $33.1M $32.4M $85.5M $138M
Diluted EPS $4.50 $4.56 $3.32 βˆ’$2.73 $1.51 $2.40 $2.33 $2.39 $6.15 $9.74
Diluted shares 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B 0.01B 0.01B 0.01B 0.01B
Cash flow
Cash from operations $259M βˆ’$72.8M βˆ’$112M $53.6M $176M $28.4M βˆ’$30.1M $117M $168M $415M
Capital expenditure $2.8M $4.8M $8.6M $7.1M $1.7M $1.4M $3.4M $2.8M $6.6M $3.9M
Free cash flow $256M βˆ’$77.6M βˆ’$121M $46.5M $174M $27.0M βˆ’$33.4M $114M $161M $411M
Depreciation and amortization $2.0M $2.8M $3.4M $3.5M $3.7M $3.4M $3.0M $2.0M $1.9M $1.9M
Stock-based compensation $2.3M $4.7M $1.6M $2.1M $2.9M $3.5M $4.0M $4.5M $4.5M $7.9M
Share buybacks β€” β€” β€” β€” β€” $20.4M $68.2M $12.5M $1.5M $9.9M
Dividends paid β€” β€” β€” β€” $47.0M $15.7M $14.0M $14.7M $18.3M $24.3M
Dividends and buybacks β€” β€” β€” β€” $47.0M $36.0M $82.2M $27.1M $19.8M $34.2M
Balance sheet
Cash and short-term investments $167M $122M $164M $167M $367M $350M $325M $307M $298M $491M
Current assets $588M $485M $416M $422M $546M $507M $439M $547M $781M $1.1B
Current liabilities $351M $183M $81.3M $144M $276M $223M $203M $302M $480M $711M
Property and equipment, net $13.1M $15.3M $19.8M $22.5M $20.4M $10.5M $10.4M $11.0M $14.5M $16.6M
Goodwill $34.9M $34.3M $32.8M $27.9M $27.9M $28.0M $28.0M $28.0M $28.0M $28.0M
Intangible assets $8.2M $7.1M $6.1M $5.0M $4.1M $3.3M $2.6M $2.2M $1.8M $1.5M
Total assets $644M $543M $477M $488M $603M $554M $489M $598M $836M $1.2B
Total liabilities $352M $185M $82.3M $147M $280M $228M $209M $307M $484M $724M
Shareholders' equity $292M $358M $395M $339M $321M $326M $281M $291M $352M $462M
Margins
Gross margin 21.7% 16.7% 17.1% βˆ’2.9% 15.8% 19.6% 19.0% 14.1% 16.1% 20.5%
Operating margin 16.6% 12.0% 8.3% βˆ’23.4% 5.9% 8.7% 9.2% 6.4% 10.1% 14.3%
EBITDA margin 16.9% 12.3% 9.1% βˆ’21.9% 6.8% 9.4% 9.8% 6.7% 10.3% 14.5%
Net margin 10.4% 8.1% 10.8% βˆ’17.9% 6.1% 7.5% 7.3% 5.6% 9.8% 14.6%
FCF margin 38.0% βˆ’8.7% βˆ’25.1% 19.5% 44.4% 5.3% βˆ’7.3% 19.9% 18.4% 43.5%
Returns
Return on capital employed 38.2% 29.8% 10.2% βˆ’16.3% 7.1% 13.5% 14.5% 12.3% 24.7% 28.4%
Return on equity 24.1% 22.2% 13.8% βˆ’11.6% 7.2% 11.8% 10.9% 11.3% 26.6% 33.8%
Return on assets 10.9% 12.1% 10.2% βˆ’8.9% 4.4% 6.6% 6.3% 5.9% 11.9% 13.6%
Return on tangible equity 28.3% 22.7% 14.6% βˆ’13.9% 8.3% 13.0% 13.2% 12.4% 26.5% 31.8%
Growth
Revenue growth β€” 32.3% βˆ’46.0% βˆ’50.4% 64.1% 29.9% βˆ’10.7% 26.0% 52.5% 8.1%
Net income growth β€” 2.4% βˆ’27.7% βˆ’182.0% β€” 60.3% βˆ’13.5% βˆ’2.2% 164.1% 61.2%
EPS growth β€” 1.3% βˆ’27.2% βˆ’182.2% β€” 58.9% βˆ’2.9% 2.6% 157.3% 58.4%
FCF growth β€” βˆ’130.3% β€” β€” 274.8% βˆ’84.5% βˆ’223.9% β€” 41.1% 155.2%
Share count change β€” 1.0% βˆ’0.6% βˆ’0.5% 1.3% 0.6% βˆ’10.9% βˆ’4.4% 2.6% 1.7%
Financial health
Current ratio 1.7x 2.6x 5.1x 2.9x 2.0x 2.3x 2.2x 1.8x 1.6x 1.6x
Quick ratio 1.7x 2.6x 5.1x 2.9x 2.0x 2.3x 2.2x 1.8x 1.6x 1.6x
Capital allocation
Capex / revenue 0.4% 0.5% 1.8% 3.0% 0.4% 0.3% 0.7% 0.5% 0.8% 0.4%
Stock comp / revenue 0.3% 0.5% 0.3% 0.9% 0.7% 0.7% 0.9% 0.8% 0.5% 0.8%
Payouts / FCF β€” β€” β€” β€” 27.0% 133.5% β€” 23.8% 12.3% 8.3%
Quality scores
Piotroski F-score β€” 4.0 4.0 3.0 6.0 6.0 3.0 5.0 6.0 5.0
Altman Z'' 5.2 8.3 11.9 6.7 5.3 6.5 6.5 5.3 5.0 4.9
Accruals ratio βˆ’29.3% 24.4% 32.2% βˆ’20.0% βˆ’27.9% 1.7% 12.1% βˆ’15.5% βˆ’11.5% βˆ’27.4%

Source: SEC EDGAR XBRL filings (CIK 0000100591). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open